Purchase this article with an account.
O.Z. Plous, E.R. Thomas, J.W. Kitchens, T.W. Stone, R.D. Isernhagen, W.J. Wood; Visual Acuity and OCT Outcomes in Patients Treated With Bevacizumab for Presumed Ocular Histoplasmosis Syndrome . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5186.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and efficacy of intravitreal bevacizumab in the treatment of presumed ocular Histoplasmosis syndrome.
A retrospective chart review was performed on the medical records of patients diagnosed with choroidal neovascularization secondary to presumed ocular Histoplasmosis syndrome treated with intravitreal bevacizumab.
Fifteen patients with choroidal nevoascularization secondary to presumed ocular Histoplasmosis syndrome were injected with bevacizumab intravitreally. Visual acuity and OCT characteristics were analyzed at baseline, as well as at one and three months post–injection (results to be presented). No adverse events occurred.
Bevacizumab is a safe and possibly effective treatment for choroidal neovascularization secondary to presumed ocular Histoplasmosis syndrome.
This PDF is available to Subscribers Only